Discipline of Economics, School of Business and Economics, National University of Ireland, Galway, Ireland.
Discipline of General Practice, School of Medicine, National University of Ireland, Galway, Ireland.
J Public Health (Oxf). 2017 Dec 1;39(4):e282-e289. doi: 10.1093/pubmed/fdw102.
Antimicrobial resistance is a major public health issue. This study examines the cost effectiveness of the SIMPle (Supporting the Improvement and Management of Prescribing for Urinary Tract Infections (UTI)) intervention to improve antimicrobial prescribing in primary care in Ireland.
An economic evaluation was conducted alongside a cluster randomized controlled trial of 30 general practices and 2560 patients with a diagnosis of UTI. Practices were randomized to the usual practice control or the SIMPle intervention (arm A or B). Data at 6 months follow-up were used to estimate incremental costs, incremental effectiveness in terms of first-line antimicrobial prescribing for UTI and cost effectiveness acceptability curves.
The SIMPle intervention was, on average, more costly and more effective than the control. The probability of intervention arm A being cost effective was 0.280, 0.995 and 1.000 at threshold values of €50, €150 and €250 per percentage point increase in first-line antimicrobial prescribing respectively. The equivalent probabilities for intervention arm B were 0.121, 0.863 and 0.985, respectively.
The cost effectiveness of the SIMPle intervention depends on the value placed on improving antimicrobial prescribing. Future studies should examine the wider and longer term costs and outcomes of improving antimicrobial prescribing.
抗菌药物耐药性是一个主要的公共卫生问题。本研究考察了 SIMPle(支持改善和管理尿路感染(UTI)处方)干预措施在爱尔兰改善初级保健中抗菌药物处方的成本效益。
在一项针对 30 家全科实践和 2560 名 UTI 诊断患者的集群随机对照试验中进行了经济评估。实践被随机分配到常规实践对照组或 SIMPle 干预组(A 组或 B 组)。使用 6 个月随访时的数据来估计增量成本、UTI 一线抗菌药物处方的增量效果和成本效益接受曲线。
SIMPle 干预平均比对照组更昂贵、更有效。在一线抗菌药物处方每增加一个百分点的阈值分别为 50 欧元、150 欧元和 250 欧元时,干预 A 组具有成本效益的概率分别为 0.280、0.995 和 1.000。干预 B 组的等效概率分别为 0.121、0.863 和 0.985。
SIMPle 干预的成本效益取决于对抗菌药物处方改善的重视程度。未来的研究应研究改善抗菌药物处方的更广泛和更长期的成本和结果。